Loading…

IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES

BackgroundRecent global estimates show that P. falciparum malaria still constitutes an enormous public health concern. Chief amongst desirable interventions is an effective vaccine that could complement existing control measures. Heterologous prime-boost vaccinations involving chimpanzee adenovirus...

Full description

Saved in:
Bibliographic Details
Published in:BMJ global health 2017-02, Vol.2 (Suppl 2), p.A30-A31
Main Authors: Afolabi, Muhammed, Mensah, Victorine, Roetynck, Sophie, Kanteh, Ebrima, Bowyer, Georgina, Ndaw, Amy, Oko, Francis, Bliss, Carly, Jagne, Ya Jankey, Cortese, Riccardo, Nicosia, Alfredo, Roberts, Rachel, D'Alessio, Flavia, Leroy, Odile, Faye, Babacar, Kampmann, Beate, Cisse, Badara, Bojang, Kalifa, Gerry, Stephen, Viebig, Nicola, Lawrie, Alison, Clarke, Ed, Ewer, Katie, Imoukhuede, Egeruan, Hill, Adrian
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A31
container_issue Suppl 2
container_start_page A30
container_title BMJ global health
container_volume 2
creator Afolabi, Muhammed
Mensah, Victorine
Roetynck, Sophie
Kanteh, Ebrima
Bowyer, Georgina
Ndaw, Amy
Oko, Francis
Bliss, Carly
Jagne, Ya Jankey
Cortese, Riccardo
Nicosia, Alfredo
Roberts, Rachel
D'Alessio, Flavia
Leroy, Odile
Faye, Babacar
Kampmann, Beate
Cisse, Badara
Bojang, Kalifa
Gerry, Stephen
Viebig, Nicola
Lawrie, Alison
Clarke, Ed
Ewer, Katie
Imoukhuede, Egeruan
Hill, Adrian
description BackgroundRecent global estimates show that P. falciparum malaria still constitutes an enormous public health concern. Chief amongst desirable interventions is an effective vaccine that could complement existing control measures. Heterologous prime-boost vaccinations involving chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP have consistently shown acceptable safety, excellent immunogenicity and substantial efficacy in African adult and paediatric populations. When licensed, malaria vaccines would preferably be given to infants receiving routine childhood immunisations. Nevertheless, no studies have evaluated the interference of ChAd63/MVA ME-TRAP when co-administered with routine Expanded Programme Immunisation (EPI) vaccines.MethodsWe enrolled 65 Gambian infants and neonates in an age de-escalating fashion, priming at 4 months, 8 weeks or 1 week of age, and randomised them to vaccine or control (EPI vaccines only) arm. Safety was assessed by the description of vaccine-related adverse events ascertained through clinical assessments, biochemical and haematological tests. Immunogenicity was evaluated by IgG ELISA, interferon-gamma ELISPOT, intra-cellular cytokine staining and flow cytometry. Antibody testing was performed to assess any interference of the EPI vaccines with responses to ChAd63/MVA ME-TRAP.ResultsOverall, the vaccination regimes were well tolerated in all age groups with no vaccine-related serious adverse events. High level IgG and antigen-specific T cell responses were generated after boosting with MVA, with T cell responses highest in the infants 8 week old at priming dose. EPI vaccines retained unchanged antibody levels in all age groups.ConclusionsPotent humoral and cellular immunity induced by heterologous prime-boost immunisation with ChAd63 and MVA ME-TRAP did not interfere with the immunogenicity of co-administered routine EPI vaccines in infants and neonates. Potent T cell induction was again observed with the vectored malaria vaccines despite co-administration with EPI vaccines.
doi_str_mv 10.1136/bmjgh-2016-000260.79
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2551755331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2551755331</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1599-838ad7e185d1226a02c39ee3dd713f7615d5d2f22249f6fefe52553e09fdd3673</originalsourceid><addsrcrecordid>eNqNkU9PwjAYhxejiQT5Bh6aeB70D1vpsYwNmmyt2QqGUzNYpxIR3OTgZ_JLWpwHjl76vsnvefoefp53j-AQIRKONvvd84uPIQp9CCEO4ZCyK6-HYcB8yuDk-mK_9QZtu3MYou6BYc_7Flm2lGoeSxEJvQYqARlPeS64v4ojrfJ4BlY8ioSMCyAKIJUGPElc5ILpGkTK57NMSFHonGuhJHgSegFytdROAfGjuNAl4CDncqYyUTg9UlLnKk3dqt3B9AzMeTYVXLo14VIXwNFAxkpyHRd33k1dvrV28Df73jKJdbTwUzUXEU_9DQoY8ydkUlbUoklQIYzDEuItYdaSqqKI1DREQRVUuMYYj1kd1ra2AQ4CYiGrq4qElPS9h-7fY3P4ONn20-wOp-bdnTQORNTBBDlq3FHb5tC2ja3NsXndl82XQdCcmzG_zZhzM6ZrxlDmtFGnufR_xg-rEYKL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2551755331</pqid></control><display><type>article</type><title>IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES</title><source>BMJ Open Access Journals</source><source>PubMed Central</source><creator>Afolabi, Muhammed ; Mensah, Victorine ; Roetynck, Sophie ; Kanteh, Ebrima ; Bowyer, Georgina ; Ndaw, Amy ; Oko, Francis ; Bliss, Carly ; Jagne, Ya Jankey ; Cortese, Riccardo ; Nicosia, Alfredo ; Roberts, Rachel ; D'Alessio, Flavia ; Leroy, Odile ; Faye, Babacar ; Kampmann, Beate ; Cisse, Badara ; Bojang, Kalifa ; Gerry, Stephen ; Viebig, Nicola ; Lawrie, Alison ; Clarke, Ed ; Ewer, Katie ; Imoukhuede, Egeruan ; Hill, Adrian</creator><creatorcontrib>Afolabi, Muhammed ; Mensah, Victorine ; Roetynck, Sophie ; Kanteh, Ebrima ; Bowyer, Georgina ; Ndaw, Amy ; Oko, Francis ; Bliss, Carly ; Jagne, Ya Jankey ; Cortese, Riccardo ; Nicosia, Alfredo ; Roberts, Rachel ; D'Alessio, Flavia ; Leroy, Odile ; Faye, Babacar ; Kampmann, Beate ; Cisse, Badara ; Bojang, Kalifa ; Gerry, Stephen ; Viebig, Nicola ; Lawrie, Alison ; Clarke, Ed ; Ewer, Katie ; Imoukhuede, Egeruan ; Hill, Adrian</creatorcontrib><description>BackgroundRecent global estimates show that P. falciparum malaria still constitutes an enormous public health concern. Chief amongst desirable interventions is an effective vaccine that could complement existing control measures. Heterologous prime-boost vaccinations involving chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP have consistently shown acceptable safety, excellent immunogenicity and substantial efficacy in African adult and paediatric populations. When licensed, malaria vaccines would preferably be given to infants receiving routine childhood immunisations. Nevertheless, no studies have evaluated the interference of ChAd63/MVA ME-TRAP when co-administered with routine Expanded Programme Immunisation (EPI) vaccines.MethodsWe enrolled 65 Gambian infants and neonates in an age de-escalating fashion, priming at 4 months, 8 weeks or 1 week of age, and randomised them to vaccine or control (EPI vaccines only) arm. Safety was assessed by the description of vaccine-related adverse events ascertained through clinical assessments, biochemical and haematological tests. Immunogenicity was evaluated by IgG ELISA, interferon-gamma ELISPOT, intra-cellular cytokine staining and flow cytometry. Antibody testing was performed to assess any interference of the EPI vaccines with responses to ChAd63/MVA ME-TRAP.ResultsOverall, the vaccination regimes were well tolerated in all age groups with no vaccine-related serious adverse events. High level IgG and antigen-specific T cell responses were generated after boosting with MVA, with T cell responses highest in the infants 8 week old at priming dose. EPI vaccines retained unchanged antibody levels in all age groups.ConclusionsPotent humoral and cellular immunity induced by heterologous prime-boost immunisation with ChAd63 and MVA ME-TRAP did not interfere with the immunogenicity of co-administered routine EPI vaccines in infants and neonates. Potent T cell induction was again observed with the vectored malaria vaccines despite co-administration with EPI vaccines.</description><identifier>ISSN: 2059-7908</identifier><identifier>EISSN: 2059-7908</identifier><identifier>DOI: 10.1136/bmjgh-2016-000260.79</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Age groups ; Global health ; Lymphocytes ; Malaria ; Newborn babies ; Pediatrics ; Vaccines</subject><ispartof>BMJ global health, 2017-02, Vol.2 (Suppl 2), p.A30-A31</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gh.bmj.com/content/2/Suppl_2/A30.3.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://gh.bmj.com/content/2/Suppl_2/A30.3.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,27549,27550,27924,27925,77601,77632</link.rule.ids></links><search><creatorcontrib>Afolabi, Muhammed</creatorcontrib><creatorcontrib>Mensah, Victorine</creatorcontrib><creatorcontrib>Roetynck, Sophie</creatorcontrib><creatorcontrib>Kanteh, Ebrima</creatorcontrib><creatorcontrib>Bowyer, Georgina</creatorcontrib><creatorcontrib>Ndaw, Amy</creatorcontrib><creatorcontrib>Oko, Francis</creatorcontrib><creatorcontrib>Bliss, Carly</creatorcontrib><creatorcontrib>Jagne, Ya Jankey</creatorcontrib><creatorcontrib>Cortese, Riccardo</creatorcontrib><creatorcontrib>Nicosia, Alfredo</creatorcontrib><creatorcontrib>Roberts, Rachel</creatorcontrib><creatorcontrib>D'Alessio, Flavia</creatorcontrib><creatorcontrib>Leroy, Odile</creatorcontrib><creatorcontrib>Faye, Babacar</creatorcontrib><creatorcontrib>Kampmann, Beate</creatorcontrib><creatorcontrib>Cisse, Badara</creatorcontrib><creatorcontrib>Bojang, Kalifa</creatorcontrib><creatorcontrib>Gerry, Stephen</creatorcontrib><creatorcontrib>Viebig, Nicola</creatorcontrib><creatorcontrib>Lawrie, Alison</creatorcontrib><creatorcontrib>Clarke, Ed</creatorcontrib><creatorcontrib>Ewer, Katie</creatorcontrib><creatorcontrib>Imoukhuede, Egeruan</creatorcontrib><creatorcontrib>Hill, Adrian</creatorcontrib><title>IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES</title><title>BMJ global health</title><description>BackgroundRecent global estimates show that P. falciparum malaria still constitutes an enormous public health concern. Chief amongst desirable interventions is an effective vaccine that could complement existing control measures. Heterologous prime-boost vaccinations involving chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP have consistently shown acceptable safety, excellent immunogenicity and substantial efficacy in African adult and paediatric populations. When licensed, malaria vaccines would preferably be given to infants receiving routine childhood immunisations. Nevertheless, no studies have evaluated the interference of ChAd63/MVA ME-TRAP when co-administered with routine Expanded Programme Immunisation (EPI) vaccines.MethodsWe enrolled 65 Gambian infants and neonates in an age de-escalating fashion, priming at 4 months, 8 weeks or 1 week of age, and randomised them to vaccine or control (EPI vaccines only) arm. Safety was assessed by the description of vaccine-related adverse events ascertained through clinical assessments, biochemical and haematological tests. Immunogenicity was evaluated by IgG ELISA, interferon-gamma ELISPOT, intra-cellular cytokine staining and flow cytometry. Antibody testing was performed to assess any interference of the EPI vaccines with responses to ChAd63/MVA ME-TRAP.ResultsOverall, the vaccination regimes were well tolerated in all age groups with no vaccine-related serious adverse events. High level IgG and antigen-specific T cell responses were generated after boosting with MVA, with T cell responses highest in the infants 8 week old at priming dose. EPI vaccines retained unchanged antibody levels in all age groups.ConclusionsPotent humoral and cellular immunity induced by heterologous prime-boost immunisation with ChAd63 and MVA ME-TRAP did not interfere with the immunogenicity of co-administered routine EPI vaccines in infants and neonates. Potent T cell induction was again observed with the vectored malaria vaccines despite co-administration with EPI vaccines.</description><subject>Age groups</subject><subject>Global health</subject><subject>Lymphocytes</subject><subject>Malaria</subject><subject>Newborn babies</subject><subject>Pediatrics</subject><subject>Vaccines</subject><issn>2059-7908</issn><issn>2059-7908</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><recordid>eNqNkU9PwjAYhxejiQT5Bh6aeB70D1vpsYwNmmyt2QqGUzNYpxIR3OTgZ_JLWpwHjl76vsnvefoefp53j-AQIRKONvvd84uPIQp9CCEO4ZCyK6-HYcB8yuDk-mK_9QZtu3MYou6BYc_7Flm2lGoeSxEJvQYqARlPeS64v4ojrfJ4BlY8ioSMCyAKIJUGPElc5ILpGkTK57NMSFHonGuhJHgSegFytdROAfGjuNAl4CDncqYyUTg9UlLnKk3dqt3B9AzMeTYVXLo14VIXwNFAxkpyHRd33k1dvrV28Df73jKJdbTwUzUXEU_9DQoY8ydkUlbUoklQIYzDEuItYdaSqqKI1DREQRVUuMYYj1kd1ra2AQ4CYiGrq4qElPS9h-7fY3P4ONn20-wOp-bdnTQORNTBBDlq3FHb5tC2ja3NsXndl82XQdCcmzG_zZhzM6ZrxlDmtFGnufR_xg-rEYKL</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Afolabi, Muhammed</creator><creator>Mensah, Victorine</creator><creator>Roetynck, Sophie</creator><creator>Kanteh, Ebrima</creator><creator>Bowyer, Georgina</creator><creator>Ndaw, Amy</creator><creator>Oko, Francis</creator><creator>Bliss, Carly</creator><creator>Jagne, Ya Jankey</creator><creator>Cortese, Riccardo</creator><creator>Nicosia, Alfredo</creator><creator>Roberts, Rachel</creator><creator>D'Alessio, Flavia</creator><creator>Leroy, Odile</creator><creator>Faye, Babacar</creator><creator>Kampmann, Beate</creator><creator>Cisse, Badara</creator><creator>Bojang, Kalifa</creator><creator>Gerry, Stephen</creator><creator>Viebig, Nicola</creator><creator>Lawrie, Alison</creator><creator>Clarke, Ed</creator><creator>Ewer, Katie</creator><creator>Imoukhuede, Egeruan</creator><creator>Hill, Adrian</creator><general>BMJ Publishing Group LTD</general><scope>9YT</scope><scope>ACMMV</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201702</creationdate><title>IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES</title><author>Afolabi, Muhammed ; Mensah, Victorine ; Roetynck, Sophie ; Kanteh, Ebrima ; Bowyer, Georgina ; Ndaw, Amy ; Oko, Francis ; Bliss, Carly ; Jagne, Ya Jankey ; Cortese, Riccardo ; Nicosia, Alfredo ; Roberts, Rachel ; D'Alessio, Flavia ; Leroy, Odile ; Faye, Babacar ; Kampmann, Beate ; Cisse, Badara ; Bojang, Kalifa ; Gerry, Stephen ; Viebig, Nicola ; Lawrie, Alison ; Clarke, Ed ; Ewer, Katie ; Imoukhuede, Egeruan ; Hill, Adrian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1599-838ad7e185d1226a02c39ee3dd713f7615d5d2f22249f6fefe52553e09fdd3673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age groups</topic><topic>Global health</topic><topic>Lymphocytes</topic><topic>Malaria</topic><topic>Newborn babies</topic><topic>Pediatrics</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Afolabi, Muhammed</creatorcontrib><creatorcontrib>Mensah, Victorine</creatorcontrib><creatorcontrib>Roetynck, Sophie</creatorcontrib><creatorcontrib>Kanteh, Ebrima</creatorcontrib><creatorcontrib>Bowyer, Georgina</creatorcontrib><creatorcontrib>Ndaw, Amy</creatorcontrib><creatorcontrib>Oko, Francis</creatorcontrib><creatorcontrib>Bliss, Carly</creatorcontrib><creatorcontrib>Jagne, Ya Jankey</creatorcontrib><creatorcontrib>Cortese, Riccardo</creatorcontrib><creatorcontrib>Nicosia, Alfredo</creatorcontrib><creatorcontrib>Roberts, Rachel</creatorcontrib><creatorcontrib>D'Alessio, Flavia</creatorcontrib><creatorcontrib>Leroy, Odile</creatorcontrib><creatorcontrib>Faye, Babacar</creatorcontrib><creatorcontrib>Kampmann, Beate</creatorcontrib><creatorcontrib>Cisse, Badara</creatorcontrib><creatorcontrib>Bojang, Kalifa</creatorcontrib><creatorcontrib>Gerry, Stephen</creatorcontrib><creatorcontrib>Viebig, Nicola</creatorcontrib><creatorcontrib>Lawrie, Alison</creatorcontrib><creatorcontrib>Clarke, Ed</creatorcontrib><creatorcontrib>Ewer, Katie</creatorcontrib><creatorcontrib>Imoukhuede, Egeruan</creatorcontrib><creatorcontrib>Hill, Adrian</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>BMJ global health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Afolabi, Muhammed</au><au>Mensah, Victorine</au><au>Roetynck, Sophie</au><au>Kanteh, Ebrima</au><au>Bowyer, Georgina</au><au>Ndaw, Amy</au><au>Oko, Francis</au><au>Bliss, Carly</au><au>Jagne, Ya Jankey</au><au>Cortese, Riccardo</au><au>Nicosia, Alfredo</au><au>Roberts, Rachel</au><au>D'Alessio, Flavia</au><au>Leroy, Odile</au><au>Faye, Babacar</au><au>Kampmann, Beate</au><au>Cisse, Badara</au><au>Bojang, Kalifa</au><au>Gerry, Stephen</au><au>Viebig, Nicola</au><au>Lawrie, Alison</au><au>Clarke, Ed</au><au>Ewer, Katie</au><au>Imoukhuede, Egeruan</au><au>Hill, Adrian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES</atitle><jtitle>BMJ global health</jtitle><date>2017-02</date><risdate>2017</risdate><volume>2</volume><issue>Suppl 2</issue><spage>A30</spage><epage>A31</epage><pages>A30-A31</pages><issn>2059-7908</issn><eissn>2059-7908</eissn><abstract>BackgroundRecent global estimates show that P. falciparum malaria still constitutes an enormous public health concern. Chief amongst desirable interventions is an effective vaccine that could complement existing control measures. Heterologous prime-boost vaccinations involving chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP have consistently shown acceptable safety, excellent immunogenicity and substantial efficacy in African adult and paediatric populations. When licensed, malaria vaccines would preferably be given to infants receiving routine childhood immunisations. Nevertheless, no studies have evaluated the interference of ChAd63/MVA ME-TRAP when co-administered with routine Expanded Programme Immunisation (EPI) vaccines.MethodsWe enrolled 65 Gambian infants and neonates in an age de-escalating fashion, priming at 4 months, 8 weeks or 1 week of age, and randomised them to vaccine or control (EPI vaccines only) arm. Safety was assessed by the description of vaccine-related adverse events ascertained through clinical assessments, biochemical and haematological tests. Immunogenicity was evaluated by IgG ELISA, interferon-gamma ELISPOT, intra-cellular cytokine staining and flow cytometry. Antibody testing was performed to assess any interference of the EPI vaccines with responses to ChAd63/MVA ME-TRAP.ResultsOverall, the vaccination regimes were well tolerated in all age groups with no vaccine-related serious adverse events. High level IgG and antigen-specific T cell responses were generated after boosting with MVA, with T cell responses highest in the infants 8 week old at priming dose. EPI vaccines retained unchanged antibody levels in all age groups.ConclusionsPotent humoral and cellular immunity induced by heterologous prime-boost immunisation with ChAd63 and MVA ME-TRAP did not interfere with the immunogenicity of co-administered routine EPI vaccines in infants and neonates. Potent T cell induction was again observed with the vectored malaria vaccines despite co-administration with EPI vaccines.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/bmjgh-2016-000260.79</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-7908
ispartof BMJ global health, 2017-02, Vol.2 (Suppl 2), p.A30-A31
issn 2059-7908
2059-7908
language eng
recordid cdi_proquest_journals_2551755331
source BMJ Open Access Journals; PubMed Central
subjects Age groups
Global health
Lymphocytes
Malaria
Newborn babies
Pediatrics
Vaccines
title IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A28%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IMMUNOGENICITY%20OF%20MALARIA-VECTORED%20VACCINES%20IS%20NOT%20AFFECTED%20BY%20CO-ADMINISTRATION%20WITH%20ROUTINE%20EPI%20VACCINES%20IN%20A%20RANDOMISED%20CONTROLLED%20TRIAL%20IN%20GAMBIAN%20INFANTS%20AND%20NEONATES&rft.jtitle=BMJ%20global%20health&rft.au=Afolabi,%20Muhammed&rft.date=2017-02&rft.volume=2&rft.issue=Suppl%202&rft.spage=A30&rft.epage=A31&rft.pages=A30-A31&rft.issn=2059-7908&rft.eissn=2059-7908&rft_id=info:doi/10.1136/bmjgh-2016-000260.79&rft_dat=%3Cproquest_cross%3E2551755331%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1599-838ad7e185d1226a02c39ee3dd713f7615d5d2f22249f6fefe52553e09fdd3673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2551755331&rft_id=info:pmid/&rfr_iscdi=true